People & Business :: M&A
DSM looking at options to exit its caprolactam business
12:44 PM MDT | July 3, 2013 | Natasha Alperowicz
DSM today declined to comment on a Bloomberg report that it is considering exiting the caprolactam business. However, it confirmed previously announced plans to reduce its exposure to the merchant caprolactam market. “DSM is considering various options and has nothing new to report to its previous public statements,” the company said. DSM is among the world’s largest merchant sellers of caprolactam, with about 60% of its production at Geelen, Netherlands, and Augusta, GA, being sold to third parties. In addition, a joint venture with...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee